Monday May 22, 7:02 am Eastern Time
Company Press Release
Mayo Clinic Study Findings Presented at North American Society of Pacing and Electrophysiology (NASPE) 21st Annual Scientific Sessions, Washington, DC
CardioDynamics (CDIC) Proprietary BioZ ICG Technology Optimizes Care of Heart Failure Pacemaker Patients
SAN DIEGO--(BW HealthWire)--May 22, 2000-- Researchers from the Mayo Clinic, Rochester, Minnesota, presented significant clinical study results involving CardioDynamics' (Nasdaq: CDIC - news) BioZ©at the North American Society of Pacing and Electrophysiology 21st Annual Scientific Sessions held May 17-20, 2000 in Washington, DC. The results validate the use and importance of CDIC's proprietary Impedance Cardiography (ICG) technology for atrioventricular interval (AVI) optimization after implantation of a biventricular pacing system in heart failure patients.
Biventricular pacing is an expanding new treatment for congestive heart failure and optimization of the AVI is crucial for improving blood flow in these patients. In the Mayo Clinic Study, the BioZ's ICG technology was shown to be as effective as the widely used Doppler/echocardiography (Echo) technique. Advantages of ICG over echocardiography are its ease of use, time efficiency, and cost-effectiveness.
Michael K. Perry, CardioDynamics' Chief Executive Officer, stated, ``The results of this Study are very exciting. The medical community continues to find new applications for our proprietary ICG technology to optimize treatment, improve quality of life, and reduce cost. With over one million pacemaker patients in the U.S. and almost five million heart failure patients who potentially may need biventricular pacing, this is yet another expansive application for our technology.''
David L. Hayes, M.D., Vice Chair, Cardiovascular Division and Professor of Medicine, Mayo Clinic, Rochester, Minnesota, stated, ``The excellent correlation between the BioZ and Echo/Doppler method in this Study provides the medical community with a potential alternative for determining AVI optimization. Previous studies have shown the importance of AVI optimization in patients with standard dual-chamber pacemakers, and the BioZ's noninvasive ICG technology has also shown in this Study to be effective in optimizing AVI following implant of a P-synchronous biventricular pacing system. ICG technology may result in an improvement in the traditional care of pacemaker patients.''
Perry continued, ``We are honored to have our technology selected for study by the world renown Mayo Clinic. Research from prestigious institutions, such as the Mayo Clinic, facilitates the adoption of our technology. With approximately 620 specialty physicians who implant pacemakers, we believe this latest research will assist in developing sales in this $16 million pacing market.''
The Mayo Clinic is devoted to its mission of pursuing superior biomedical research that enhances the care of the Mayo patient and leads to decreasing the burden of human disease. More than five million people have been treated at Mayo Clinic since its frontier founding. Today it encompasses three clinics and four hospitals in three states, employing more than 25,000 physicians, scientists, nurses and allied health workers.
CardioDynamics, with headquarters in San Diego, is a medical technology and information solutions company committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The Company's primary products, the BioZ© System and BioZ.com©, utilize proprietary Impedance Cardiography (ICG), DISQ(TM) technology, and the Z MARC(TM) algorithm to noninvasively provide medical professionals with hemodynamic data previously not available in the physician's office and many hospital settings. Just as Electrocardiography (ECG) noninvasively measures the heart's electrical characteristics, ICG makes it possible to noninvasively measure the heart's mechanical (blood flow) characteristics. Physicians around the world are currently using the BioZ products, including major medical centers such as Harvard Brigham & Women's (Boston), Mayo Clinic (Rochester), UCSF Stanford Health Care (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). For additional information, please refer to the Company's Web site at www.cdic.com.
Forward-Looking (Safe Harbor) Statement:
Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz© device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1999 Form 10-KSB. The Company does not undertake to update the disclosures contained in this press release. |
